Understanding the environmental drivers of clinical azole resistance in *Aspergillus* species

Pooja Sen¹, Mukund Vijay¹, Shweta Singh², Saif Hameed², Pooja Vijayaraghavan¹

¹Antimycotic and Drug Susceptibility Laboratory, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, Uttar Pradesh - India
²Amity Institute of Biotechnology, Amity University Haryana, Gurugram (Manesar) - India

**ABSTRACT**

Aspergilli are ubiquitous fungal pathogens associated with severe life-threatening infections, especially in immunocompromised patients. Azoles are the first line of defence in the fight against most *Aspergillus*-related infections. However, resistance to these therapeutic compounds has developed, which is mainly due to the existence of mutations in lanosterol 14 alpha-demethylase (Cyp51A), a crucial enzyme in the pathway that produces ergosterol and is the target of azole antifungals. Azole-based antifungal medications are ineffective because of infections brought on by azole-resistant *Aspergillus* species, leading to a high fatality rate. However, resistant *Aspergillus* isolates have also been isolated from azole-naïve patients. Global agricultural practices promote the use of azole fungicides to protect crops from phytopathogens. Usage of azole fungicides on a large scale has been linked to the development of resistance among *Aspergillus* species prevalent in the environment. The infections caused by these azole-resistant *Aspergillus* species cannot be treated by the available azole drugs, in turn leading to high morbidity and mortality rates. Thus, knowledge of the environmental drivers and comprehending the genetic basis of fungal drug resistance evolution is pertinent, considering increasing numbers of patients with COVID-19 infections who are sensitive to opportunistic fungal infections. This article emphasises the prevalence and underlying mechanisms of azole resistance in *Aspergillus* species, with a focus on environmental triggers and resistance development. It also highlights the need for regular surveillance of pesticide use in agriculture, detection of triazole-resistant *Aspergillus* species in environmental and clinical settings and development of new antifungal drugs.

**Keywords:** *Aspergillus*, Azole resistance, Biofilm, cyp51A gene, Environmental origin, Triazoles

**Introduction**

The saprophytic genus *Aspergillus* is universal in the environment that releases large numbers of conidiospores. After inhalation, they either reach the terminal airways or settle in large groups in the upper ventilatory system and cause sensitisation. The small size of the spores, thermostolerance, resistance to oxidative damage and the capacity to create proteolytic or even immunosuppressive enzymes are among *Aspergillus'* biological characteristics which permits growth at body temperature (1,2). *Aspergillus* species reported as human pathogens are *Aspergillus fumigatus*, *Aspergillus niger*, *Aspergillus flavus* and *Aspergillus nidulans*. Bronchitis, invasive aspergillosis (IA), and chronic pulmonary aspergillosis (CPA) are all signs of *Aspergillus* infection. In addition, severe asthma with fungal hypersensitivity and allergic bronchopulmonary aspergillosis (ABPA) are allergic symptoms of inhaled *Aspergillus* (3).

Current antifungal therapy for aspergillosis falls into three main categories: polyenes, echinocandins, and azoles. Of these, azoles are the drug of choice for treating *Aspergillus* infection. In addition, they are the only orally available antifungal agents for therapy and are essential for long-term treatment (3). *A. fumigatus* has developed azole resistance over the past few decades because of long-term azole therapy for aspergillosis in the clinical environment (4). Furthermore, azole-resistant isolates of *Aspergillus* detected in azole-naïve (5) individuals indicate that there may be a second route for the establishment of resistance through *A. fumigatus* azole fungicide exposure in agro ecosystems.
Global prevalence of Aspergillosis

Aspergillosis can be either chronic or acute. Most commonly, aspergillosis diseases are CPA, IA and bronchitis (6). *Aspergillus* species are responsible for >2,00,000 cases of IA annually, as shown in Table I (7).

<table>
<thead>
<tr>
<th>Fungal disease</th>
<th>Global burden</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthmatic allergic bronchopulmonary aspergilosis</td>
<td>~4,800,000</td>
<td>Adults only, rare in children</td>
</tr>
<tr>
<td>Cystic fibrosis–related allergic bronchopulmonary aspergilosis</td>
<td>~6675</td>
<td>Adults only, starts from age 4</td>
</tr>
<tr>
<td>Invasive aspergilosis</td>
<td>~3,00,000</td>
<td>About 10 million at risk annually</td>
</tr>
<tr>
<td>Chronic pulmonary aspergilosis</td>
<td>~3,00,000</td>
<td></td>
</tr>
</tbody>
</table>

In immunocompromised individuals, such as those with severe neutropenia, individuals who had bone marrow transplant or solid organ transplants, those with advanced acquired immunodeficiency syndrome or with chronic granulomatous illness, IA can develop (10). Invasion of the lungs by *Aspergillus* leads to tissue damage leading to sepsis and sometimes haemoptysis in later stages (11). In addition to these classic risk factors for IA, liver cirrhosis, tuberculosis, diabetes mellitus and persistent lung disease can also develop (12-15). CPA is an infectious disease that progressively damages lung tissue. This is especially true for immunocompromised people with a previous or underlying lung disease, such as tuberculosis or chronic obstructive pulmonary disease (COPD). Awareness of this debilitating and ultimately deadly infection is growing. It is tentatively estimated that there are 3 million CPA (Chronic pulmonary aspergillosis) patients worldwide (6). Among Asian countries, the highest CPA burden was recorded in India (209,147) (15), followed by Pakistan (55,509) (16), Bangladesh (20,720) (17), Nepal (6,611) (18) and Sri Lanka (2,886) (19). Patients with ABPA frequently experience uncontrolled asthma or repeated infections brought on by bronchiectasis, which progresses to lung damage, respiratory failure, and ultimately death. ABPA contamination in the Indian subcontinent is summarised in Table II (9,21).

**Antifungal agents to treat aspergillosis**

In general, there are three different types of antifungal medications used to treat *Aspergillus*-related illnesses: polyenes (amphotericin B), azoles (itraconazole, voriconazole and posaconazole) and echinocandins (caspofungin).

**Polyenes**

Polyenes are large macrolide structures with amphipathic nature (Fig. 1). The oldest class of antifungal drugs are the polyenes, which include nystatin, amphotericin B and pimaricin. Of these, amphotericin B is the only drug used to treat systemic infections. Polyenes promote channelling in fungal membranes by interacting with sterols in cell membranes (ergosterol in fungal cells), which leads to changing the permeability of the membrane leading to the leaking of intracellular components. The major antifungal medication used to treat severe *Aspergillus* infections is amphotericin B. However, it has detrimental side effects including fever, chills, hypotension, tachypnoea, as well as renal toxicity such as renal ischaemia, hypokalaemia, tubular acidosis and reduced erythropoiesis in the kidney (10).

<table>
<thead>
<tr>
<th>Country</th>
<th>Chronic pulmonary aspergillosis</th>
<th>Invasive aspergillosis</th>
<th>Allergic bronchopulmonary aspergillosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Burden Rate/100,000</td>
<td>Burden Rate/100,000</td>
<td>Burden Rate/100,000</td>
</tr>
<tr>
<td>India (15)</td>
<td>209,147 24</td>
<td>–</td>
<td>1,380,000 114</td>
</tr>
<tr>
<td>Pakistan (16)</td>
<td>55,509 70</td>
<td>10,949 5.9</td>
<td>94,358 51</td>
</tr>
<tr>
<td>Bangladesh (17)</td>
<td>20,720 41</td>
<td>5166 5.1</td>
<td>90,262 56</td>
</tr>
<tr>
<td>Nepal (18)</td>
<td>6,611 24.2</td>
<td>1119 4.0</td>
<td>9546 35</td>
</tr>
<tr>
<td>Sri Lanka (19)</td>
<td>2,886 14.4</td>
<td>229 1.1</td>
<td>10,344 49</td>
</tr>
</tbody>
</table>

**Fig. 1 - Structure of polyene antifungal compounds.**
Azoles

The primary treatment includes azoles used to treat aspergillosis (20). This class of antifungals includes medicines with an azole ring (Fig. 2) that stops a variety of fungi from growing (22). Clotrimazole, econazole, ketoconazole, miconazole, and tioconazole are examples of two-nitrogen-atom imidazole. Triazoles, in contrast, have three nitrogen atoms in the azole ring (fluconazole, itraconazole, posaconazole and voriconazole). The antifungal effects of azole compounds were first described in 1944 (23). The first compound was imidazole, followed by triazole. The first azole antifungal that could be applied topically in a therapeutic setting was chlormidazole in 1958. Other imidazole-azole antifungals such as clotrimazole and miconazole were thereafter made available for topical application, and econazole was released in 1974 (24). The first drug was ketoconazole, an oral medication for systemic fungal infections, albeit its usage was constrained by its toxicity (25,26). Fluconazole and itraconazole, the two most used systemic triazoles, were first made available in the United States in 1990. Fluconazole and itraconazole have sufficient antifungal activity and are far less harmful than ketoconazole (27). Itraconazole and fluconazole are less toxic than ketoconazole and have adequate antifungal action (27). Voriconazole and posaconazole were the second-generation triazoles to be made available in the late 1990s and early 2000s. They have proven to be incredibly powerful against A. fumigatus (28) and are being utilised to manage fluconazole-resistant strains (29). Triazoles under investigation include albaconazole (30), isavuconazole and pramiconazole (31).

Azoles work by blocking the cytochrome P-450-dependent enzyme lanosterol demethylase, also known as 14α-sterol demethylase or P-450<sub>DM</sub> which is necessary for the formation of ergosterol, a crucial component of fungal plasma membranes (32). Exposure to azoles in A. fumigatus decreases ergosterol levels and accumulates 14α-methylated sterols (33). This leads to a change in the structure and shape of the membrane, affects nutrient uptake and chitin synthesis, and inhibits fungal growth (34,35). On fungal cells, ergosterol also exhibits hormone-like characteristics that promote growth and reproduction (34). This function can also be impaired if the breakdown of ergosterol is more than 99% complete (34). Triazole is indispensable for long-term treatment, because of the fact that it is the only anti-Aspergillus drug that can be taken orally (36). Although itraconazole is still frequently used to treat the long-established non-invasive allergic type of aspergillosis (38), voriconazole is still advised as the first-line treatment for AI (34,35,37). Amphotericin B, a more lethal medication than triazoles, is the only available alternative.

Echinocandins

The most recent addition to the family of antifungal drugs are the echinocandins, with the first example, caspofungin, entering clinical use a decade ago (39). They are lipopeptide compounds that inhibit the enzyme (1,3) beta-D-glucan synthase, which produces glucan, the primary building block of fungal cell walls. Caspofungin (Fig. 3) is non-competitively effective against A. fumigatus, A. flavus and A. terreus. It is indicated for Aspergillus infections among those patients unresponsive or intolerant to other treatments. However, it has not been considered for first-line treatment (39).

Fig. 2 - Structure of azole antifungals (imidazoles; two nitrogen in the azole ring and triazoles; three nitrogen in the azole ring).
Environmental drivers of *Aspergillus* azole resistance

Plants are attacked by various pathogenic fungi that cause a variety of disease such as late blight, powdery mildew, leaf spot, blast, downy mildew, fruit rot, rust, etc. Throughout the world, the usage of synthetic insecticides and pesticides is quite common to overcome crop diseases and failure. However, these can have a significant negative impact on the environment (40). Thousands of tonnes of azoles are sold every year for crop protection. The advantages of azole pesticides include low cost and a diverse range of antifungal activity (41). Hexaconazole, propiconazole, triadimefon and tricyclazole are some of the prominent triazole fungicides available in the international market (42). The long-term stability of azoles is a crucial characteristic. With very slight modifications to their chemical composition, several azoles can continue to function for months in agricultural habitats (soil and water). Singh and Dureja (43) reported that hexaconazole can remain in soil for a long time due to its hydrophobic properties. Azoles are effective against several plant fungal diseases listed in Table II. The major metabolite of triadimefon, triadimenol, has a half-life in soil that varies from 110 to 375 days. The plants are sprayed several times per growing season at a dose of 100 g/ha, which is recommended to combat fungal diseases (41). There are currently 32 commercially available azole fungicides for crop protection (44). Several foods have been found to contain azole residues, for example, in samples of commercially available strawberries, grapes or mint. Therefore, there is evidence that large amounts of antifungal residues, especially azoles, can remain in the environment.

**TABLE III - Azole fungicides used in market (42-44)**

<table>
<thead>
<tr>
<th>Azole fungicides</th>
<th>Crops</th>
<th>Diseases caused by <em>Aspergillus</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Triadimefon</td>
<td>Wheat, pea, grapes, coffee, mango, chilies, soybean</td>
<td>Bunt of wheat, powdery mildew, rust, powdery mildew, coffee rust, rust</td>
</tr>
<tr>
<td>Bitertanol</td>
<td>Apple, groundnut, tea, wheat, groundnut</td>
<td>Scab, rust, tikka, blister blight, Karnal bunt</td>
</tr>
<tr>
<td>Flusilazole</td>
<td>Grapes, apple, rice, chilies</td>
<td>Powdery mildew, scab, sheath blight</td>
</tr>
<tr>
<td>Hexaconazole</td>
<td>Apple, rice, groundnut, mango, soybean, tea</td>
<td>Blister blight, powdery mildew rust, scab, blast, sheath blight, tikka leaf spot</td>
</tr>
<tr>
<td>Tebuconazole</td>
<td>Wheat, groundnut, chili, rice</td>
<td>Blast sheath blight, loose smut, flag smut, collar rot, root rot, stem rot, fruit rot, powdery mildew</td>
</tr>
<tr>
<td>Difenoconazole</td>
<td>Apple, groundnut, rice, chili, cumin, onion</td>
<td>Fruit rot, blight powdery mildew, sheath blight, scab, leaf spot rust, purple blotch</td>
</tr>
<tr>
<td>Tricyclazole</td>
<td>Paddy</td>
<td>Blast</td>
</tr>
</tbody>
</table>

**Resistance to azoles developing in Aspergillus clinical isolates**

Recent years have seen a rise in the concern of azole therapy resistance in patients with *Aspergillus* infections. *A. fumigatus*, which causes around 80% of invasive infections, has been found to possess the highest azole resistance (45). Azole resistance has also been demonstrated in other species including *A. niger*, *A. terreus* and *A. flavus* (46). Infections with resistant *Aspergillus* strains lead to the effectiveness of azole antifungals, resulting in high mortality rates. Azole-resistant strains of *Aspergillus* were reported in the United States in the late 1990s (47). There have been numerous reports of infections with resistant strains in Europe, particularly in the UK and the Netherlands. Since that time, practically every European nation has reported cases of azole resistance, including Germany, Ireland, Italy, Austria, Denmark, France, Sweden, Portugal, Spain and Turkey (25,48-64). A surveillance study from the UK reported that the prevalence of azole resistance in *A. fumigatus* increased from 0.43% in 1998-2011 to 2.2% in 2015-2017 (65). A multicentre study conducted in Taiwan found a 4% prevalence rate for *A. fumigatus* resistant to azoles (66). Among Asian countries, Taiwan and China were the first to report resistance to azoles (67,68). Furthermore, this study has sparked significant worries about the use of azole antifungal medications to treat IA in the future.

The increase in resistance to triazoles in the clinical setting can be explained by two main phenomena: (a) an azole-resistant *Aspergillus* strain was found after long-term treatment with azoles in patients with cavernous lung disease and aspergillosis. When susceptible *Aspergillus* strains...
acquire resistance to the pharmacological stress response of prolonged azole therapy, they develop resistance. Numerous point mutations were found in the azole-resistant *A. fumigatus* isolate, especially at codons 54 and 220 of *cyp51A* (69). Several resistance mechanisms associated with *cyp51A* have been identified in patients specifically associated with azole therapy (70). Human-to-human transmission is therefore highly unlikely and spread of resistance is very rare.

(b) Azole fungicides are frequently employed to protect crops in agricultural settings and are structurally like medical triazoles. *Aspergillus* species are found in soil together with other plant pathogens. Azoles that attack plant pathogens can also affect *Aspergillus* species found in the same ecosystem (3). Fungicides used repeatedly over a long period of time can create persistent selection pressure and lead to the development of resistant *Aspergillus* species. As a result, the environment contains *Aspergillus* species that are azole-resistant. When these conidia are inhaled by susceptible individuals, *Aspergillus* species become resistant to triazoles used for treatment. Several cases of triazole-resistant aspergillosis in humans and animals without prior triazole treatment have been reported worldwide (71,72).

**Resistance to triazoles in Aspergillus clinical isolates is associated with the use of azole fungicides in agriculture**

Many major agricultural fungi have developed resistance because of the site-specific mode of action and widespread application of 14α-demethylase inhibitor (DMI) fungicides to prevent post-harvest spoiling by plant-pathogenic fungus. Azole overuse in agriculture may have an impact on saprophytic microbiota species as well as plant-pathogenic fungi (73). The soil provides a natural habitat for several fungi that could be harmful, including *Aspergillus*, *Coccidioides*, *Histoplasma* and *Cryptococcus*. Recently, the use of azole pesticides has been identified as a significant contributing cause in the increasing prevalence of *A. fumigatus* isolates with a particular mechanism of resistance comprising the TR34/L98H mutation in the *cyp51A* gene.

Snelders et al.’s (74) findings that were obtained from both clinical and environmental sources exhibited cross-resistance to five triazole-DMI fungicides, notably bromeunonazole, propiconazole, epoxiconazole, tebuconazole and difenoconazole, support the notion that *Aspergillus* species become resistant to triazoles as a result of environmental use of azole fungicide (74). Additionally, these researchers noted that all these five DMI-triazoles have efficacy against wild-type *A. fumigatus* but not against the resistant TR34/L98H *A. fumigatus* because of their molecular structure, which is similar to drug triazoles and when attached to the target enzyme, acquire a same conformation (74). In a related study from India, four of the five triazole DMIs – bromeunonazole, tebuconazole, epoxiconazole and difenoconazole – showed substantially higher MIC (Minimum inhibitory concentration) values with TR34/L98H-resistant *A. fumigatus* from environmental and clinical samples than with wild-type non-resistant isolates. These drugs are known to have performance comparable molecular structures to drug triazoles (75).

In 2020, a study from India found that patients who had never taken triazole therapy had developed resistance, raising the possibility that environmental transmission may contribute to the emergence of resistance (5). Most of the resistance mechanisms found in patients without prior treatment with azole are resistance mechanisms associated with TR (tandem repeats). Most *Aspergillus* isolates from the environment also possessed this resistance mechanism (TR34/L98H or TR46/Y121F/T289A). Norway, the Netherlands, Denmark, the United Kingdom and India are some of the countries where all these resistant environmental isolates have been found (76). Thus, retrieval of a similar resistance mechanism from environmental isolates as patient isolates supported an environmental pathway for resistance development.

**Environmental-induced mutations in azole-resistant Aspergillus isolates**

Ergosterol is a crucial and distinct element of the fungal plasma membrane that gives the cell membrane stability and permeability. The enzyme cytochrome P450, also called sterol-14α-demethylase, converts lanosterol into ergosterol. *cyp51A* is a gene that codes for the cytochrome P450 enzyme. The ergosterol biosynthetic pathway is the general target ofazole antifungals. Triazoles hinder the cytochrome P450 enzyme from performing its lanosterol-converting role in the ergosterol biosynthetic pathway, and causes the depletion of ergosterol and the deleterious build-up of lanosterol (74). Azole resistance is brought on by mutations in the *cyp51A* gene that change the *cyp51A* protein’s structure and reduce the enzymes’ affinity forazole therapies.

Various changes in *cyp51A* resulting in a pan-azole-resistant phenotype have been reported in *A. fumigatus* isolates from environment and clinical sources worldwide. The most frequent mechanisms of resistance reported in environmental and clinical strains of *A. fumigatus* are mutations in the TR34/L98H and TR46/Y121F/T289A genes. These changes in the *cyp51A* gene comprise TRs within the gene’s promoter region (77). The *cyp51A* gene is overexpressed because of the insertion of 34 base pair (bp) TRs (TR34) into the *cyp51A* gene’s promoter region and the substitution of the leucine 98 amino acid coding for histidine (TR34/L98H) (78). According to Table IV (77), TR34/L98H is the most typical resistance mechanism found in environmental and clinical strains of *A. fumigatus* in many different nations. Another resistance mechanism which has been proven is TR46/Y121F/T289A (Fig. 4) where a 46 bp TR promoter region of the *cyp51A* gene has substitutions of threonine 289 for alanine and tyrosine 121 for phenylalanine (TR46/Y121F/T289A), resulting in an elevated resistance to voriconazole in *A. fumigatus* (79). One of the most frequently detected mechanisms of resistance in environmental isolates from Europe are TR34/L98H and TR46/Y121F/T289A, and their emergence has already been connected to the widespread use of azole-based agricultural fungicides (tebuconazole, hexaconazole and epoxiconazole). Fungicide use is rising in India, where it already accounts for 19% of all pesticide use (80). Even though Europe is the worldwide leader in agricultural fungicide use (40%), it is followed by Japan and Latin America. In contrast to Europe, the United...
States uses very less azoles in agriculture (http://ec.europa.eu/food/fs/se/ssc/out278_en.pdf). Therefore, no TR34/L98H mutation has been reported in environmental clinical isolates in the United States, but this mutation has been found in the European setting and now also in India (77).

An environmental study conducted examined a variety of soil and air samples from different regions of India. In their study, soil samples were taken from natural soils (where no azole fungicides were used). The samples tested positive for Aspergillus strains, but no resistant isolates were detected. Their findings were supported with those of the Dutch environmental study, which discovered that none of the A. fumigatus isolates cultured in natural soil exhibited azole resistance (81). Therefore, commercialised compost and samples taken from fields where fungicides are consistently treated can be the focus of environmental research to find TR34/L98H mutations in A. fumigatus isolates.

In environmental samples from China (82), certain novel mutations (G448S, TR46/Y121F/T289A) with 46 bp triple TRs in the promoter region have been discovered. Other Asian nations like India, Iran and Kuwait have demonstrated azole resistance in environmental Aspergillus strains (83,84). About 2% of Aspergillus species in Kuwait were found to be azole resistant, according to another study on environmental resistance (84). Indian researchers have reported that environmental studies on azole resistance describe the TR46/Y121F/T289A mechanism (85), and the findings indicated that 44 out of 630 A. fumigatus isolates from soil of indoor air, paddy fields, tea gardens, cotton groves, flowerpots and hospitals were resistant and managed to retain TR34/L98H resistance (75). An environmental mechanism of resistance (TR46/Y121F/1289A) in strains of A. fumigatus was also first reported in this study. In 2009, a similar mutation was discovered in a Dutch patient and has also been reported in several patients from the Netherlands (86). This survey, which took place between 2012 and 2013, studied 105 environmental samples taken from North Indian agricultural fields. The study concluded that azole fungicide-treated agricultural soils in northern India co-occurred with TR34/L98H and TR46/Y121F/T289A. The identified Indian Aspergillus strains were likely to be highly adaptable recombinant descendants of a cross between a native azole-sensitive strain from within India and azole-resistant strain that migrated from outside India, followed by a mutation, according to genomic analysis of the Indian resistance mechanism TR34/L98H (75). Reports indicated a rapid spread of this mutation in Asia (83).

<table>
<thead>
<tr>
<th>Geographic region/ references</th>
<th>Sample</th>
<th>cyp51A resistance mechanisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Netherlands (81)</td>
<td>Soil</td>
<td>Unknown, F46Y/M172V/E427K</td>
</tr>
<tr>
<td>France (87)</td>
<td>Dust from patients’ home</td>
<td>H285Y</td>
</tr>
<tr>
<td>Germany (88)</td>
<td>Soil</td>
<td>G54A, M220I</td>
</tr>
<tr>
<td>India (89)</td>
<td>Soil</td>
<td>G54E</td>
</tr>
<tr>
<td>Taiwan (90)</td>
<td>Soil, air</td>
<td>Wild-type cyp51A or SNPs</td>
</tr>
<tr>
<td>France (91)</td>
<td>Soil</td>
<td>Unknown, P216L</td>
</tr>
<tr>
<td>Colombia (92)</td>
<td>Soil</td>
<td>TR46/Y121F/T289A, TR34/L98H and TR53</td>
</tr>
<tr>
<td>India (77)</td>
<td>Environment</td>
<td>TR34/L98H</td>
</tr>
<tr>
<td>India (93)</td>
<td>Azole-naive patient</td>
<td>G54E</td>
</tr>
<tr>
<td>India (5)</td>
<td>Azole-naive patient</td>
<td>G54R, P216L and Y431C</td>
</tr>
</tbody>
</table>

SNP = single nucleotide polymorphism.

Multiple triazole-resistant A. fumigatus isolates with the TR/L98H genotype were found in patients with chronic respiratory disease, according to a different study that was carried out for the first time in India (75). Only Europe and

---

**Fig. 4** - Various azole resistance mechanisms in *Aspergillus fumigatus* (a) Wild-type fungi in the presence of azole drug unable to make ergosterol. (b) Mutations in the cyp51A region alter the structural modifications of the enzyme leading to reduce azole affinity. (c) Insertion of 34 and 46 base pair in the promoter region along with point mutation in the cyp51A region causes overexpression of the gene. (d) Overexpression of efflux pump genes causing a reduced intracellular accumulation of azole drug.
China have been described as having the TR/L98H mutation linked to pan-azole resistance in *A. fumigatus* (70,81). The two triazole-resistant *A. fumigatus* isolates are epidemiologically unrelated, share the same TR genotypes, and come from patients with no prior history of exposure to azoles or travel to Europe, suggesting that they most likely mutated and developed resistance as a result of exposure to the environment in India. The two isolates were phylogenetically distinct from TR/L98H, which contained the 25 *A. fumigatus* isolates from Dutch. The usage of azole fungicides in the environment may be a contributing factor in the propagation of this resistance mechanism (TR/L98H) in *A. fumigatus* isolates. A total of 43.7% of *Aspergillus* isolates found in 25 agricultural soil samples were found to be resistant to azoles, according to a recent environmental study in India (94).

Other non-synonymous hotspot mutations in the *cyp51A* gene have also been discovered in azole-resistant *A. fumigatus* strains, in addition to the TR34/L98H and TR46/Y121F/T289A alterations. While resistance to ITC (Itraconazole) and POS (Posaconazole) was provided by the glycosyl modification mutations 54 (G54) and 138 (G138), lower susceptibility to ITC and POS related to the glycosyl 448 (G448S) (95) mutation-related resistance to VRC. Methionine 220 (M220) amino acid substitution was also linked to a pronounced pattern of decreased sensitivity to triazoles (70). There have also been sporadic reports of other point mutations, including P216L, F219C, F219I, A284T, Y431C, G432S and G434C (86). Patients who received around 4 months (range 3 weeks to 23 months) of long-term azole treatment for persistent aspergillosis have been discovered to have the point mutations G54E/R/V and M220I/V/T/K (96). It is important to mention here that studies conducted in India, Tanzania, Romania and Germany found G54 mutations in environmental isolates of *A. fumigatus* (97). An environmental study in India found an azole-resistant *Aspergillus* species with a G54E mutation (89). This point mutation in the *cyp51A* gene is commonly seen in patients undergoing long-term azole therapy (89). In another study in India, *A. fumigatus* isolates with G54R, P216L and Y431C mutations were obtained from azole corpus patients (4). The MICs of many additional point mutations, including F46Y, M172V, N248T, D255E and E427K, have been discovered in azole-susceptible and azole-resistant *Aspergillus* isolates. However, this is not always restricted to clinical drug states. Therefore, it is important to identify sources of infection, whether the patient is hospitalised or a source of in-hospital contamination, due to the potential for aerosol transmission from patient to patient (103).

### Azole-resistant *Aspergillus* biofilms

*Aspergillus* is an opportunistic airborne pathogen capable of forming biofilms in clinical settings or in immunocompromised patients with underlying conditions leading to allergic aspergillosis or IA (104). Biofilms are a community of cells strongly adherent to abiotic and biotic surfaces and surrounded by an extracellular matrix (ECM) composed of polysaccharides. The ECM acts as a protective sheet and external scaffold for adhesion and integration with the surface, and cell spreading for subsequent invasion. This protective layer becomes more sensitive to antifungal drug treatments and attacks immune cells, making them harder to fight (105). Possible factors contributing to drug resistance in *Aspergillus* spp. biofilms are: upregulation of efflux pump genes such as *AfuMDR4*, *MDR1*, *MDR2*, *MDR4*; induction of the HSP90 stress response pathway, which increases resistance to the antifungal drugs amphotericin B and caspofungin; by extracellular DNA which reduces drug sensitivity by preventing the drug from reaching its cellular target through ECM and sister cell formation while acting as drug-tolerant cells to form new biofilms (106).
The most important factor in IPA (Invasive pulmonary aspergillosis) and aspergilloma is biofilm formation. Fungal components such as drug transporters, secondary metabolites and cell wall components promote biofilm formation in host cells and are resistant to antifungal drug treatment (107). Biofilm formation, which helps to penetrate the host immune system and reduce the patient’s immune competence, also contributes to increased resistance to triazoles (108). A study showed that under in vitro conditions, A. fumigatus formed multicellular biofilms of polysyntene sheets that could resist the effects of antifungal drugs (109). Another study also showed an effect of itraconazole on hyphal germination and biofilm formation at an early stage, but no effect on mature biofilms, suggesting a predominance of resistant biofilms (110). Biofilms in the lungs are difficult to diagnose because they occur after mature biofilms form. In the adult stage, this tissue in the lungs develops into a more complex tissue with dense ECM and limited oxygen, which encourages further growth. This makes it increasingly difficult for immune cells to recognise and influence them. It also worsens when other microbial biofilms persist and are difficult to remove with antifungal drugs, particularly in cystic fibrosis (111). Therefore, a comprehensive analysis and understanding of Aspergillus biofilms is required to develop new and improved antifungal targets for the treatment of complex biofilm-related diseases (107).

Future directions

Azole resistance in environmental Aspergillus spp. is a matter of grave clinical concern as transfer of resistance from environment to clinical settings is inevitable. India needs to impose strict regulatory compliance to ensure regulated usage of pesticides in agricultural fields. Further studies are warranted to understand the level of transfer of resistance from the field to clinic. This can be undertaken in a state-wise study by mapping the mutations that are unique to the region. Additional studies focusing on the usage of azole fungicides and the presence of azole residues in developed environments are needed, because the amounts used or quantities present are not often measured or reported.

More surveillance, accurate data collection and comprehensive resistance surveillance programmes in agricultural ecosystems are needed to study the magnitude of the emerging problem of azole resistance. It will be very important to identify tipping points to ensure the agronomic use of fungicides without jeopardising their treatment goals. Research at the epidemiological level can uncover geographic differences in the emergence of resistance and help identify areas with high levels of resistance. Further, to overcome antifungal resistance in clinical settings, development of new antifungals with new drug target site is needed.

Acknowledgements

Authors would like to thank Amity University Uttar Pradesh for providing the infrastructure and facilities for research.

Disclosures

Conflict of interest: The authors declare no conflict of interest.

Financial support: Authors would like to thank CSIR for providing financial support in the form of Senior Research Fellowship (09/915(0013)/2018-EMR-I) to PS. Authors’ contributions: PS performed literature search and drafted the manuscript; MV and SS performed literature search; SH critically analysed the manuscript; PV conceptualised the idea of review writing and critically analysed the manuscript.

References


52. Escribano P, Recio S, Peláez T, Bouza E, Guinea J. Aspergillus fumigatus strains with mutations in the cyp51A gene do not


80. Thind TS. Changing cover of fungicide umbrella in crop protection. Indian Phytopathol. 2007;60:421-433. [CrossRef]


© 2022 The Authors. Drug Target Insights - ISSN 1777-3928 - www.aboutscience.eu/dti


